vTv Therapeutics Inc (VTVT) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $13. H.C. Wainwright advised their investors in a research report released on Sep 26, 2016.
On the company’s financial health, vTv Therapeutics Inc reported $-0.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Mar 1, 2016. Analyst had a consensus of $-0.47. The company had revenue of $.23 million for the quarter, compared to analysts expectations of $.03 million. The company’s revenue was down -75.3 % compared to the same quarter last year.
In a different news, on Dec 16, 2015, Noel Joseph Spiegel (director) purchased 5,710 shares at $6.20 per share price. According to the SEC, on Sep 28, 2015, Paul G Savas (director) purchased 5,000 shares at $6.62 per share price. On Aug 5, 2015, Steven Michael Cohen (director) purchased 5,000 shares at $15.00 per share price, according to the Form-4 filing with the securities and exchange commission.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. The Company provides a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a range of human diseases including central nervous system disorders metabolic disorders inflammation and cancer. The Company provides programs for the treatment of Alzheimers disease (AD) and type II diabetes. Its lead candidate is Azeliragon (TTP488) and its type II diabetes drug candidates include Glucokinase Activator (TTP399) and GLP-1r Agonist (TTP273). The Company also offers products for the prevention of muscle weakness and the treatment of inflammatory disorders which include HPP593 HPP737 and HPP971. The Company utilizes TTP Translational Technology to discover small molecule therapeutics for diseases and to validate biological pathways and targets.